(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/207822 A1

(51) International Patent Classification:
A61P 11/06 (2006.01) *A61P 37/00* (2006.01)
A61P 17/00 (2006.01) *C07D 471/04* (2006.01)
A61P 17/14 (2006.01) *A61K 31/437* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/021634

(22) International Filing Date:
26 March 2025 (26.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24167017.3 27 March 2024 (27.03.2024) EP

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **JOHNSON, Patrick Stephen**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **MIN, Geanna**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **HOLMSTRØM, Thomas**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **CLEMENTSON, Sebastian**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **MARTIN-GAGO, Pablo**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **MÅNSSON, Kristoffer**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **JØRGENSEN, Morten**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **DACK, Kevin Neil**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **JOHN DE GROOT, Marcel**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: STAT6 DEGRADERS





FIG. 1



(I)

(57) Abstract: The present disclosure relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

[Continued on next page]

WO 2025/207822 A1

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*